BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

The American pharma giant tested its mRNA Covid-19 vaccine against the coronavirus mutants spreading rapidly through the U.K. and South Africa.

Pfizer-BioNTech Vaccine Appears Resistant To New Covid Variant, Study Finds, As U.S. Records Deadliest Day

Pfizer Inc. and German partner BioNTech SE said Friday an in vitro study found that their COVID-19 vaccine neutralizes the two new highly infectious variants that have emerged in the U.K. and South Africa. The results were published on the preprint service bioRxiv and have not yet been peer-reviewed.

Pfizer and BioNTech say COVID-19 vaccine neutralizes mutation found in new U.K., South Africa variants

The research, which has not yet been peer-reviewed, suggested the Pfizer-BioNTech vaccine worked to neutralize the so-called N501Y mutation.

Pfizer vaccine appears to neutralize a key mutation of Covid variants found in UK, South Africa

The EU is doubling its purchases of the Pfizer-BioNTech coronavirus vaccine at a time of growing concern over its rollout.

EU agrees new Pfizer Covid vaccine deal and secures nearly half its annual output

New York and Mainz, Germany, January 8, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB) that shows the antibodies from people who have received the Pfizer-BioNTech COVID-19 vaccine effectively neutralize SARS-CoV-2 with a key mutation that is also found in two highly transmissible strains. The results were published on the preprint server bioRxiv and are available here.

An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission

The study is preliminary and has not yet been reviewed by experts, a key step for medical research.

Pfizer study suggests vaccine works against virus variant

Pfizer Inc (NYSE: PFE)/BionNTech SE (NASDAQ: BNTX) COVID-19 showed signs of working against a mutation found in two highly-contagious COVID-19 virus variants detected in the U.K. and South Africa in a laboratory study conducted by Pfizer. What Happened: These positive findings were spotted during the study, conducted in collaboration with the University of Texas Medical Branch, reports Reuters.

Pfizer Study Shows Vaccine Efficacious Against COVID-19 Variant

The COVID-19 vaccine from pharmaceutical companies Pfizer and BioNTech looks to be effective against 16 different mutations of the coronavirus, according to a study that has not yet undergone peer review. As Reuters reported, the study, by researchers at Pfizer and the University of Texas Medical Branch, suggests the vaccine will not need to be tweaked in order to work against a seemingly more contagious variant of the coronavirus that arose in the UK.

Early study suggests Pfizer vaccine effective against COVID-19 mutations

Preliminary data shows Pfizer's mRNA vaccine can effectively neutralize coronavirus variants in lab tests.

Pfizer vaccine appears effective against rapidly spreading coronavirus variants

MAINZ, GERMANY, January 7, 2021 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in the peer-reviewed journal Science. The publication titled “A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis” summarizes the findings on the disease-suppressing effects of a non-inflammatory, nucleoside-modified mRNA vaccine in several clinically relevant mouse models of multiple sclerosis (MS).

BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science

Moderna

Messenger RNA or mRNA technology has come of age, with the first two Covid-19 vaccines (Moderna and BioNTech/Pfizer) approved by Western regulators being based on the technology. The technology promises big benefits for drug development, considering the relatively quick development times.

Moderna Or BioNTech: Better Stock To Play The mRNA Revolution?

With the U.K. entering a third nationwide lockdown and the COVID-19 pandemic raging through the rest of Europe, vaccines approved for emergency use are in high demand.  What Happened: The European Union is negotiating with Pfizer Inc. (NYSE: PFE)-BioNTech SE – ADR (NASDAQ: BNTX) to procure an additional 100 million doses of the pair's coronavirus vaccine candidate, with an option to buy 200 million more doses, according to a Bloomberg report.

EU In Talks To Buy Up To 300M More Coronavirus Vaccine Doses From Pfizer-BioNTech

MAINZ, GERMANY, January 5, 2021 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO and Co-founder Ugur Sahin, M.D., will present a corporate overview and update at the virtual 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021, at 10.50am ET.

BioNTech to Present at the 39th Annual J.P. Morgan Healthcare Conference

The United States Food and Drug Administration has warned against changing the dosing regimen, interval, or mixing of COVID-19 vaccines in a statement issued Monday. What Happened: The health agency recognized that available data indicates the use of two specified doses of the COVID-19 vaccines — made by Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) — at specified intervals.

FDA Warns Against Tinkering With Pfizer, Moderna Vaccine Regimens After White House Advisor's Comments

ICON

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ:ICLR), a global provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries and government and public health organisations, today announced it provided clinical trial services to the Pfizer (NYSE:PFE) and BioNTech SE (Nasdaq: BNTX) investigational COVID-19 vaccine programme. Pfizer and BioNTech were the first to announce positive efficacy results from a Phase 3, la

ICON Supports Pfizer and BioNTech on the Investigational COVID-19 Vaccine Trial

A lot of money could ride on a planned second version of Pfizer's coronavirus vaccine.

Pfizer's Next Multibillion-Dollar COVID Vaccine Move

The company sounded alarm bells about the widening gap between the initial shot and booster of BNT162b2.

Pfizer Criticizes Sudden Change in Coronavirus Vaccine Dosing Regime in the U.K.

PFE stock does not include any value to the Pfizer-BioNTech partnership and the developments of a game-changing Covid-19 vaccine. The post Why Pfizer is the Cheapest Coronavirus Vaccine Play appeared first on InvestorPlace.

Why Pfizer is the Cheapest Coronavirus Vaccine Play

The U.K. National Health Service has pushed back the window for people to receive the second dose of the coronavirus vaccine made by Pfizer and BioNTech — to a duration the companies tested on only a small percentage of patients.

U.K. health service pushes back interval for delivering second Pfizer coronavirus vaccine to a duration company says is untested

The EU's total order now stands at 300 million.

Pfizer and BioNTech Supplying 100 Million Additional Doses of Coronavirus Vaccine to European Union

European Commission President Ursula von der Leyen took to Twitter to announce Tuesday that the European Union will purchase an additional 100 million doses of the Pfizer (NYSE: PFE)-BioNTech (NASDAQ: BNTX) coronavirus vaccine.  We decided to take an additional 100 million doses of the #BioNTech /@Pfizer vaccine, which is already being used to vaccinate people across the EU.

European Union Set To Purchase 100M More Doses Of Pfizer COVID-19 Vaccine

Pfizer Inc. and its German partner BioNTech SE will supply an additional 100 million doses of their COVID-19 vaccine to the 27 member states of the European Union, the companies said in a joint statement. The move comes after the European Commission exercised an option to purchase the extra doses that was granted as part of an agreement signed in November.

Pfizer and BioNTech to supply additional 100 million COVID vaccine doses to EU in 2021

For all the hoopla, PFE stock has already seen the benefit of the Covid-19 vaccine and needs new catalysts. Still, long-term investors may want it's healthy dividend.

Pfizer's All-in Costs Show Vaccine Probably Won't Move the Needle Much

With its solid dividend yield and reasonable valuation, there's more to like about PFE stock than just Pfizer's pandemic catalyst. The post As Vaccine Excitement Fades, Buy the Pullback in Pfizer appeared first on InvestorPlace.

News for BioNTech SE Stock (BNTX)